Platycodin D confers oxaliplatin Resistance in Colorectal Cancer by activating the LATS2/YAP1 axis of the hippo signaling pathway

Oxaliplatin-based therapy is used as a first-line drug to treat metastatic colorectal cancer. However, long-term and repeated drug treatment resulted in drug resistance and the failure of chemotherapy. Various natural compounds were previously reported to act as chemosensitizers to reverse drug resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chien-Hao, Baskaran, Rathinasamy, Ng, Shawn Shang-Chuan, Wang, Tso-Fu, Li, Chi-Cheng, Ho, Tsung-Jung, Hsieh, Dennis Jine-Yuan, Kuo, Chia-Hua, Chen, Ming-Cheng, Huang, Chih-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969589/
https://www.ncbi.nlm.nih.gov/pubmed/36860929
http://dx.doi.org/10.7150/jca.77322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969589/
https://www.ncbi.nlm.nih.gov/pubmed/36860929
http://dx.doi.org/10.7150/jca.77322

Ejemplares similares